2-碘-5-甲基噻唑 | 847547-16-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-碘-5-甲基噻唑
• 英文名称: 2-iodo-5-methylthiazole
• 英文别名: 2-Iodo-5-methyl-1,3-thiazole
• CAS: 847547-16-4
• 化学式: C₄H₄INS
• 分子量: 225.053
• InChiKey: HUSIZGWEEAVFKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)异吲哚啉e-2-羧酸叔丁酯 、 2-碘-5-甲基噻唑 生成 5-(5-Methyl-thiazol-2-yl)-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES

  摘要：

  本发明涉及式I的化合物，其中R1，R2和在规范中定义，并且其药学上可接受的酸加合盐。

  公开号：

  US20090203665A1
• 作为产物：
  描述：

  2-溴-5-甲基噻唑 在 正丁基锂 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 1.17h， 生成 2-碘-5-甲基噻唑
  参考文献：
  名称：

  EP1721905

  摘要：

  公开号：

文献信息

• Direct Transformation of Arylamines to Aryl Halides via Sodium Nitrite and <i>N</i> -Halosuccinimide
  作者：Sushobhan Mukhopadhyay、Sanjay Batra

  DOI：10.1002/chem.201803347

  日期：2018.10.1

  A one‐pot universal approach for transforming arylamines to aryl halides via reaction with sodium nitrite (NaNO2) and N‐halosuccinimide (NXS) in DMF at room temperature under metal‐ and acid‐free condition is described. This new protocol that is complementary to the Sandmeyer reaction, is suggested to involve the in situ generation of nitryl halide induce nitrosylation of aryl amine to form the diazo

  描述了一种在室温下在无金属和无酸条件下，通过与亚硝酸钠（NaNO 2）和N-卤代琥珀酰亚胺（NXS）在DMF中反应，将芳基胺转化为芳基卤化物的一锅通用方法。建议与桑德迈尔反应互补的这一新方案涉及原位产生的硝基卤化物引起芳基胺的亚硝化反应，形成重氮中间体，将其卤化以提供芳基卤化物。
• Photochromic polymers bearing various diarylethene chromophores as the pendant: synthesis, optical properties, and multicolor photochromism
  作者：Hiroyasu Nishi、Tomoko Namari、Seiya Kobatake

  DOI：10.1039/c1jm12707a

  日期：——

  Photochromic polymers with various diarylethene derivatives were synthesized by a conventional radical polymerization of styrene derivatives having diarylethene chromophores as the pendant. All the polymers exhibited reversible photochromism in the film as well as in solution, while the photocyclization conversion in the film decreased in comparison with that in solution because of a restriction of the conformational structure in the solid state. Although the photocyclization and photocycloreversion quantum yields at the initial stage of the reactions in the film were comparable to those in solution, the apparent cycloreversion quantum yield decreased along with the reaction, which is derived from a distribution of the quantum yields in the solid state. Finally, the photochromic terpolymers consisting of three diarylethene monomers which show photochromism changing color to cyan, magenta, and yellow were synthesized. The terpolymers were demonstrated to show bright colors including black, green, red, and blue both in solution and in the solid state by selective bleaching processes. Such multicolor photochromic polymers composed of diarylethene derivatives have a potential for rewritable photochromic display devices.

  合成了具有多种二芳基乙烯衍生物的光敏聚合物，这是通过对具有二芳基乙烯色团作为侧链的苯乙烯衍生物进行常规自由基聚合获得的。所有聚合物在薄膜和溶液中均表现出可逆的光致变色特性。然而，由于固态中构象结构的限制，薄膜中的光环化转化率与溶液中相比有所降低。尽管在反应初期，薄膜中的光环化和光环反转量子产率与溶液中相当，但随着反应的进行，明显的环反转量子产率下降，这源于固态中量子产率的分布。最后，合成了由三种二芳基乙烯单体组成的光敏三元聚合物，其光致变色改变为青色、品红色和黄色。这些三元聚合物通过选择性漂白过程在溶液和固态中表现出明亮的颜色，包括黑色、绿色、红色和蓝色。由二芳基乙烯衍生物组成的这种多色光敏聚合物在可重写的光致变色显示设备中具有潜在应用。
• Substituted acylpiperazine derivatives
  申请人：Alberati-Giani Daniela

  公开号：US20050059668A1

  公开（公告）日：2005-03-17

  The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  该发明涉及以下式中的化合物，其中取代基如规范中定义，并且其药用可接受的酸盐。该发明还涉及治疗精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及其他认知过程受损的疾病的方法，如注意力缺陷障碍或阿尔茨海默病。
• [EN] MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR DE LA PROSTACYCLINE (PGI2) UTILES POUR LE TRAITEMENT DE TROUBLES LIÉS À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2009117095A1

  公开（公告）日：2009-09-24

  The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  本发明涉及式（XIIIa）的酰胺衍生物及其药物组合物，其调节PGI2受体的活性。本发明的化合物和药物组合物适用于治疗以下疾病的方法：肺动脉高压（PAH）；特发性PAH；家族性PAH；与胶原血管疾病、先天性心脏病、门脉高压、HIV感染、药物或毒素摄入、遗传性出血性毛细血管扩张症、脾切除术、肺静脉闭塞性疾病（PVOD）或肺毛细血管血管瘤病（PCH）相关的PAH；具有明显静脉或毛细血管受累的PAH；血小板聚集；冠状动脉疾病；心肌梗死；短暂性缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在介入治疗或冠状动脉旁路手术个体中或患有心房颤动的个体中；动脉粥样硬化；动脉血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或眼内压异常的其他眼部疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥反应；多发性硬化；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• [EN] QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE À UTILISER EN TANT QU'INHIBITEURS DE BROMODOMAINE
  申请人：KAINOS MEDICINE INC

  公开号：WO2016186453A1

  公开（公告）日：2016-11-24

  Provided is a novel quinoline derivative inhibiting the bromodomain and extra terminal domain (BET) proteins, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of a precancerous transformation or a cancer.

  提供了一种新颖的喹啉衍生物，能够抑制溴结构域和额外末端结构域（BET）蛋白，以及包含该衍生物的药物组合物，可用于预防或治疗癌前病变或癌症。